trial

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCTId NCT04822883
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 37 (actual)
Sponsored by Recognify Life Sciences
Primary completion 2021-10-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
Single
Start
2021-04-26
Primary completion
2021-10-28
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
RL-007

Sponsors

Recognify Life SciencesLead Sponsor

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

1 total
Long Beach, United States

Linked catalysts

1
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia — primary completion2021-10-28

Facts & assertions

4 sourced
Enrollment
37
Phase
PHASE2
Primary Completion Date
2021-10-28
Status
COMPLETED
relationships
The graph out of here
drug
RL-007
drug
lead_sponsor
Recognify Life Sciences
company
indication
Cognitive Impairment
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person